MedTrace Logo

Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters

NCT00157651 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2008-06-17

No results posted yet for this study

Summary

This study examines whether low intensity, dose adjusted warfarin prolongs the time to mechanical failure of hemodialysis catheters without resulting in an unacceptable rate of bleeding.

Conditions

Interventions

DRUG

warfarin

Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9

DRUG

placebo

matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor

Sponsors & Collaborators

  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • Catherine M Clase, MD · Associate Professor, Medicine

  • Alistair J Ingram, MD · Associate Professor, Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-02-28
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00157651 on ClinicalTrials.gov